SCHEMBL3229932

SCHEMBL3229932

CCc1nc2c(c(=O)[nH]c(=O)n2Cc2ccc(OC)cc2OC)n1C

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.52
KDM4E B2RXH2 4/20 0.52
HPGD P15428 4/20 0.52
NPSR1 Q6W5P4 2/20 0.52
KMT2A Q03164 7/20 0.47
MEN1 O00255 6/20 0.47
RXFP1 Q9HBX9 1/20 0.47
ADORA3 P0DMS8 1/20 0.46
MAPT P10636 2/20 0.45
GAA P10253 1/20 0.45
HTT P42858 1/20 0.45
ALOX12 P18054 1/20 0.45
MAPK1 P28482 1/20 0.45
LMNA P02545 1/20 0.44
TP53 P04637 3/20 0.44
POLB P06746 2/20 0.42
XBP1 P17861 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3236024 0.77 MAPT (0.51) ALDH1A1KDM4ENPSR1KMT2AMEN1
SCHEMBL3231780 0.76 MEN1 (0.45) ALDH1A1KDM4EHPGDNPSR1KMT2A
SCHEMBL4172007 0.75 KDM4E (0.43) ALDH1A1KDM4EHPGDNPSR1RXFP1
SCHEMBL28301483 0.74 PNP (0.55) KDM4EHPGDADORA3MAPK1
SCHEMBL3227594 0.72 PDE4A (0.55) ALDH1A1KDM4EHPGDNPSR1RXFP1
SCHEMBL21463867 0.71 KDM4E (0.48) ALDH1A1KDM4EKMT2AMEN1RXFP1
SCHEMBL27033303 0.70 BRD4 (0.41) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL29344263 0.69 KDM4E (0.40) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL2775003 0.69 AGTR1 (0.49) ALDH1A1KDM4EHPGDNPSR1RXFP1
SCHEMBL29937239 0.69 KDM4E (0.40) ALDH1A1KDM4EKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2146996-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT AstraZeneca AB (SE) 2010-01-27 EP disclosed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
WO-2008130314-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT ASTRAZENECA AB (SE) 2008-10-30 WO disclosed
WO-2008130314-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT ASTRAZENECA AB (SE) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023704-A1 Novel Compounds 737 GRPR, GABRB1, GABBR1 ALDH1A1 1248/4885KDM4E 3435/4885HPGD 1486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.